ClinicalTrials.gg
CompletedNCT00471328ENESTUpdated Jun 12, 2012Results posted

Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib

A Phase 3 interventional study of Nilotinib and Best Supportive Care (BSC) +/- imatinib or sunitinib in Gastrointestinal Stromal Tumors, sponsored by Novartis Pharmaceuticals. Completed at 35 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-06-12.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
248
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing nilotinib in Gastrointestinal Stromal Tumors — none open to participants now, none under way, none of them phase 3. nilotinib · Gastrointestinal Stromal Tumors.

Enrollment
2nd of 14
248 · median 35
Started
2007
the only one that year
Phase 3
4 of 14
none open now
Registered
3rd of 14
by date
Lead sponsor
12 of 14
Novartis Pharmaceuticals

Among the 14 studies testing nilotinib in Gastrointestinal Stromal Tumors, this one is the 2nd largest by enrollment, is the only one that started in 2007, is one of 4 in phase 3, and was the 3rd registered.

Gastrointestinal Stromal Tumors

343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.

Browse Gastrointestinal Stromal Tumors studies →

Open to participants now

None of the 14 studies testing nilotinib in Gastrointestinal Stromal Tumors is open now. The open studies under Gastrointestinal Stromal Tumors, anywhere →

About nilotinib

nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing nilotinib in Gastrointestinal Stromal Tumors as a file.
02

Study summary

The study evaluated the safety and efficacy of nilotinib versus current treatment in adults with gastrointestinal stromal tumors (GIST) who have either progressed or who were intolerant to the first and second line treatments.

03

Conditions studied

  • Gastrointestinal Stromal Tumors

Keywords

  • GIST
  • adults
  • imatinib resistant
  • sunitinib resistant
  • AMN107
  • nilotinib
  • treatment
  • Gastrointestinal stromal tumor (GIST)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion criteria (Core Phase):

  • Age ≥18 years
  • Radiological confirmation of disease progression during imatinib and sunitinib therapy OR intolerance to imatinib and/or sunitinib
  • At least one measurable site of disease on CT/MRI scan
  • Physically fit even if not able to work
  • Normal organ, electrolyte, and bone marrow function

Inclusion criteria (Extension Phase):

  • Patients whose tumors had progressed on the control arm and had crossed over to the nilotinib arm.
  • The study was stopped due to meeting the primary efficacy endpoint of PFS at the interim analysis.
  • Patients who were still being treated at the close of the Core study on the control arm or nilotinib arm (whose tumors have not progressed at the time of the end of the Core study).
  • Patients must have had documented, confirmed stable, partial or complete response as defined by the criteria at the time of entry into the Extension study with the exception of patients who had progressed on the control arm.

Exclusion criteria (Core Phase):

  • Previous treatment with nilotinib or any other drug in this class or other targeted therapy
  • Treatment with any cytotoxic and/or cytotoxic drug ≤ 4 weeks prior to study entry
  • Impaired cardiac function
  • Use of coumarin derivatives (i.e. warfarin, acenocoumarol, phenprocoumon)
  • Women who are pregnant or lactating

Exclusion criteria (Extension Phase):

  • Use of other anticancer treatments or investigational drugs (with exception of the study drugs)
  • Patients with a history of noncompliance with study drug treatment in the Core study protocol.

Other protocol-defined inclusion/exclusion criteria applied

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
248 participants (actual)

Study arms

  • Experimental
    Nilotinib

    400mg twice daily in core and extension phases of the study.

    Drug: Nilotinib

  • Active comparator
    Control/cross-over to Nilotinib

    In core study phase, patients in this arm received Best Supportive Care (BSC) with or without imatinib or sunitinib at the last tolerated dose or at the investigator's choice until documented disease progression followed by cross-over to nilotinib arm. Patients entering the extension study on this control arm were permitted to cross over to nilotinib arm only upon documented disease progression.

    Drug: Nilotinib · Other: Best Supportive Care (BSC) +/- imatinib or sunitinib

Interventions

  • Nilotinib 400 mg twice daily (bid)

    Also known as: AMN107, Tasigna®

  • OtherBest Supportive Care (BSC) +/- imatinib or sunitinib

    Can include pain medication, localized radiotherapy, nutritional support, and/or oxygen therapy and blood transfusions. Imatinib or sunitinib can be administered at the last tolerated dose and regimen or at the Investigator's choice.

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) From Central Radiology Review Based on Primary Analysis (Data Cut-off: June, 2008)

    Progression-free survival (PFS) is the time from date of randomization to the date of first documented progression or death due to any cause. If a participant has not had an event, progression-free survival is censored at the time of last adequate tumor assessment. Progression is defined according to Modified Response Evaluation Criteria in Solid Tumors (modified RECIST) criteria as at least a 20% increase in the sum of the longest diameter of target lesions, worsening of the non-target lesions or the appearance of one or more new lesions.

    Time frame: Up to 16 months

  2. Progression-free Survival (PFS) From Local Investigator's Assessment Based on Treatment Crossover Analysis Set

    PFS is defined as the time from the first date of cross-over to nilotinib therapy from the control arm to the date of the first observation of documented disease progression. Tumor assessment was based on the local investigator's measurement using Modified Response Evaluation Criteria in Solid Tumors (modified RECIST) criteria. Progression is defined according to modified RECIST criteria as at least a 20% increase in the sum of the longest diameter of target lesions, worsening of the non-target lesions or the appearance of one or more new lesions.

    Time frame: Up to 34 months

Secondary outcomes

  1. Overall Survival Based on Primary Analysis (Data Cut-off:June, 2008)

    Overall survival (OS) is defined as the time from date of randomization to date of death due to any cause. If a participant is not known to have died, survival will be censored at the date of last contact.

    Time frame: Up to 16 months

  2. Overall Survival During Core and Extension Phases of the Study

    Overall survival (OS) is defined as the time from date of randomization to date of death due to any cause. If a participant is not known to have died, survival will be censored at the date of last contact. This analysis included both Core and Extension data as well as survival follow up data.

    Time frame: Up to 50 months (including core, extension and follow up period)

  3. Overall Survival for Treatment Crossover Analysis Set

    For patients who crossed-over to nilotinib from the control arm, the overall survival was the time from the first dose date of nilotinib after switching from control arm to the date of death due to any cause. If death was not observed, the OS was censored at the latest date the patient was known to be alive.

    Time frame: Up to 34 months

  4. Number of Responders With Confirmed Best Overall Response of Complete Response (CR) or Partial Response (PR) From Central Radiology Review During Primary Analysis (Data Cut-off: June, 2008)

    The best overall response is the best response recorded from randomization until disease progression. The CR/PR must be confirmed by at least two determinations at least 4 weeks apart before progression. Using modified RECIST criteria, a Complete Response is defined as disappearance of all lesions, and a Partial Response is defined as either 1) at least a 30% decrease in the sum of the longest diameter of target lesions and no new lesions or progression of non-target lesions or 2) disappearance of all target lesions but persistence of one or more non-target lesion(s).

    Time frame: Up to 16 months

  5. Number of Responders With Confirmed Best Overall Response of Complete Response (CR) or Partial Response (PR) From Local Investigator's Assessment Based on Treatment Crossover Analysis Set

    The best overall response (CR/PR) must be confirmed by at least two determinations at least 4 weeks apart before progression. Using modified RECIST criteria, a Complete Response is defined as disappearance of all lesions, and a Partial Response is defined as either 1) at least a 30% decrease in the sum of the longest diameter of target lesions and no new lesions or progression of non-target lesions or 2) disappearance of all target lesions but persistence of one or more non-target lesion(s).

    Time frame: Up to 34 months

  6. Overall Clinical Benefit (Complete Response [CR]/Partial Response [PR] or Stable Disease [SD]) From Central Radiology Review Based on Primary Analysis (Data Cut-off: June, 2008)

    The overall clinical benefit includes the best overall responses of CR, PR, or SD. The best overall responses of CR/PR must be confirmed by at least two determinations at least 4 weeks apart before progression. The best overall response of SD must have at least one SD (or better) at least 6 weeks (or 6 months or 12 months as applicable) after randomization but before progression.

    Time frame: Up to 16 months

  7. Overall Clinical Benefit (Complete Response [CR]/Partial Response [PR] or Stable Disease [SD]) From Local Investigator's Assessment Based on Treatment Crossover Analysis Set

    The overall clinical benefit includes the best overall responses of CR, PR, or SD. The best overall responses of CR/PR must be confirmed by at least two determinations at least 4 weeks apart before progression. The best overall response of SD must have at least one SD (or better) at least 6 weeks (or 6 months or 12 months as applicable) after randomization but before progression.

    Time frame: Up to 34 months

07

Results

Posted May 17, 2011

Participant flow

Patients ongoing on treatment at primary analysis had option to enter extension. Patients in control arm were allowed cross over to Nilotinib arm at disease progression and considered as part of extension. Patients entering the extension part on control arm were permitted to cross over to the nilotinib only upon documented disease progression.

Core Phase
Participant flow — Core Phase
MilestoneNilotinibControl/Cross Over to Nilotinib
Started16583
Crossover to nilotinib:started extension053
Completed5816
Not completed10767
Withdrew: Adverse event186
Withdrew: Death84
Withdrew: Withdrawal by subject22
Withdrew: Abnormal laboratory value10
Withdrew: Disease progression7853
Withdrew: Administrative problem01
Withdrew: Protocol deviation01
Extension Phase
Participant flow — Extension Phase
MilestoneNilotinibControl/Cross Over to Nilotinib
Started4167
Started:crossover before primaryanalysis053
Started:crossover after primaryanalysis04
Started:crossover during extension010
Completed00
Not completed4167
Withdrew: Adverse event312
Withdrew: Withdrawal by subject02
Withdrew: Death17
Withdrew: Protocol deviation31
Withdrew: Treatment duration as per protocol01
Withdrew: Disease progression3244
Withdrew: New cancer therapy10
Withdrew: Administrative problem10

Outcome measures

PrimaryProgression-free Survival (PFS) From Central Radiology Review Based on Primary Analysis (Data Cut-off: June, 2008)

Progression-free survival (PFS) is the time from date of randomization to the date of first documented progression or death due to any cause. If a participant has not had an event, progression-free survival is censored at the time of last adequate tumor assessment. Progression is defined according to Modified Response Evaluation Criteria in Solid Tumors (modified RECIST) criteria as at least a 20% increase in the sum of the longest diameter of target lesions, worsening of the non-target lesions or the appearance of one or more new lesions.

Time frame:
Up to 16 months
Reported as:
Median · days
Progression-free Survival (PFS) From Central Radiology Review Based on Primary Analysis (Data Cut-off: June, 2008)
daysNilotinibControl/Cross Over to Nilotinib
Progression-free Survival (PFS) From Central Radiology Review Based on Primary Analysis (Data Cut-off: June, 2008)109.0 (61.0 to 113.0)111.0 (60.0 to 116.0)
SecondaryOverall Survival Based on Primary Analysis (Data Cut-off:June, 2008)

Overall survival (OS) is defined as the time from date of randomization to date of death due to any cause. If a participant is not known to have died, survival will be censored at the date of last contact.

Time frame:
Up to 16 months
Reported as:
Median · days
Overall Survival Based on Primary Analysis (Data Cut-off:June, 2008)
daysNilotinibControl/Cross Over to Nilotinib
Overall Survival Based on Primary Analysis (Data Cut-off:June, 2008)332.0 (246.0 to NA)280.0 (240.0 to 372.0)
SecondaryOverall Survival During Core and Extension Phases of the Study

Overall survival (OS) is defined as the time from date of randomization to date of death due to any cause. If a participant is not known to have died, survival will be censored at the date of last contact. This analysis included both Core and Extension data as well as survival follow up data.

Time frame:
Up to 50 months (including core, extension and follow up period)
Reported as:
Median · days
Overall Survival During Core and Extension Phases of the Study
daysNilotinibControl/Cross Over to Nilotinib
Overall Survival During Core and Extension Phases of the Study361 (265 to 425)300 (246 to 386)
SecondaryOverall Survival for Treatment Crossover Analysis Set

For patients who crossed-over to nilotinib from the control arm, the overall survival was the time from the first dose date of nilotinib after switching from control arm to the date of death due to any cause. If death was not observed, the OS was censored at the latest date the patient was known to be alive.

Time frame:
Up to 34 months
Reported as:
Median · days
Overall Survival for Treatment Crossover Analysis Set
daysControl/Cross Over to Nilotinib
Overall Survival for Treatment Crossover Analysis Set231 (196 to 327)
PrimaryProgression-free Survival (PFS) From Local Investigator's Assessment Based on Treatment Crossover Analysis Set

PFS is defined as the time from the first date of cross-over to nilotinib therapy from the control arm to the date of the first observation of documented disease progression. Tumor assessment was based on the local investigator's measurement using Modified Response Evaluation Criteria in Solid Tumors (modified RECIST) criteria. Progression is defined according to modified RECIST criteria as at least a 20% increase in the sum of the longest diameter of target lesions, worsening of the non-target lesions or the appearance of one or more new lesions.

Time frame:
Up to 34 months
Reported as:
Median · days
Progression-free Survival (PFS) From Local Investigator's Assessment Based on Treatment Crossover Analysis Set
daysControl/Cross Over to Nilotinib
Progression-free Survival (PFS) From Local Investigator's Assessment Based on Treatment Crossover Analysis Set84 (56 to 109)
SecondaryNumber of Responders With Confirmed Best Overall Response of Complete Response (CR) or Partial Response (PR) From Central Radiology Review During Primary Analysis (Data Cut-off: June, 2008)

The best overall response is the best response recorded from randomization until disease progression. The CR/PR must be confirmed by at least two determinations at least 4 weeks apart before progression. Using modified RECIST criteria, a Complete Response is defined as disappearance of all lesions, and a Partial Response is defined as either 1) at least a 30% decrease in the sum of the longest diameter of target lesions and no new lesions or progression of non-target lesions or 2) disappearance of all target lesions but persistence of one or more non-target lesion(s).

Time frame:
Up to 16 months
Reported as:
Number · Participants
Number of Responders With Confirmed Best Overall Response of Complete Response (CR) or Partial Response (PR) From Central Radiology Review During Primary Analysis (Data Cut-off: June, 2008)
ParticipantsNilotinibControl/Cross Over to Nilotinib
Number of Responders With Confirmed Best Overall Response of Complete Response (CR) or Partial Response (PR) From Central Radiology Review During Primary Analysis (Data Cut-off: June, 2008)1 (0.0 to 3.3)0 (0.0 to 0.0)
SecondaryNumber of Responders With Confirmed Best Overall Response of Complete Response (CR) or Partial Response (PR) From Local Investigator's Assessment Based on Treatment Crossover Analysis Set

The best overall response (CR/PR) must be confirmed by at least two determinations at least 4 weeks apart before progression. Using modified RECIST criteria, a Complete Response is defined as disappearance of all lesions, and a Partial Response is defined as either 1) at least a 30% decrease in the sum of the longest diameter of target lesions and no new lesions or progression of non-target lesions or 2) disappearance of all target lesions but persistence of one or more non-target lesion(s).

Time frame:
Up to 34 months
Reported as:
Number · Participants
Number of Responders With Confirmed Best Overall Response of Complete Response (CR) or Partial Response (PR) From Local Investigator's Assessment Based on Treatment Crossover Analysis Set
ParticipantsControl/Cross Over to Nilotinib
Number of Responders With Confirmed Best Overall Response of Complete Response (CR) or Partial Response (PR) From Local Investigator's Assessment Based on Treatment Crossover Analysis Set1 (0.0 to 8.0)
SecondaryOverall Clinical Benefit (Complete Response [CR]/Partial Response [PR] or Stable Disease [SD]) From Central Radiology Review Based on Primary Analysis (Data Cut-off: June, 2008)

The overall clinical benefit includes the best overall responses of CR, PR, or SD. The best overall responses of CR/PR must be confirmed by at least two determinations at least 4 weeks apart before progression. The best overall response of SD must have at least one SD (or better) at least 6 weeks (or 6 months or 12 months as applicable) after randomization but before progression.

Time frame:
Up to 16 months
Reported as:
Number · Percentage of Participants
Overall Clinical Benefit (Complete Response [CR]/Partial Response [PR] or Stable Disease [SD]) From Central Radiology Review Based on Primary Analysis (Data Cut-off: June, 2008)
Percentage of ParticipantsNilotinibControl/Cross Over to Nilotinib
CR/PR/SD52.7 (44.8 to 60.5)44.6 (33.7 to 55.9)
CR/PR/SD lasting > 6 months7.3 (3.8 to 12.4)1.2 (0.0 to 6.5)
CR/PR/SD lasting > 12 months0.6 (0.0 to 3.3)0 (0 to 0)
SecondaryOverall Clinical Benefit (Complete Response [CR]/Partial Response [PR] or Stable Disease [SD]) From Local Investigator's Assessment Based on Treatment Crossover Analysis Set

The overall clinical benefit includes the best overall responses of CR, PR, or SD. The best overall responses of CR/PR must be confirmed by at least two determinations at least 4 weeks apart before progression. The best overall response of SD must have at least one SD (or better) at least 6 weeks (or 6 months or 12 months as applicable) after randomization but before progression.

Time frame:
Up to 34 months
Reported as:
Number · Percentage of Participants
Overall Clinical Benefit (Complete Response [CR]/Partial Response [PR] or Stable Disease [SD]) From Local Investigator's Assessment Based on Treatment Crossover Analysis Set
Percentage of ParticipantsControl/Cross Over to Nilotinib
CR/PR/SD37.3 (25.8 to 50.0)
CR/PR/SD lasting > 6 months7.5 (2.5 to 16.6)
CR/PR/SD lasting > 12 months6.0 (1.7 to 14.6)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nilotinib(Core +Extension)—81/165 (49.1%)159/165 (96.4%)
Control(Core + Extension)—27/83 (32.5%)73/83 (88%)
Crossover Nilotinib Therapy—32/67 (47.8%)58/67 (86.6%)
Most frequent serious events
Showing 10 of 119
Most frequent serious events
EventNilotinib(Core +Extension)Control(Core + Extension)Crossover Nilotinib Therapy
General physical health deteriorationGeneral disorders16/1653/8310/67
Abdominal painGastrointestinal disorders21/1655/833/67
AnaemiaBlood and lymphatic system disorders6/1657/835/67
DyspnoeaRespiratory, thoracic and mediastinal disorders4/1651/834/67
VomitingGastrointestinal disorders9/1651/831/67
Oedema peripheralGeneral disorders0/1650/833/67
PyrexiaGeneral disorders5/1652/831/67
ConstipationGastrointestinal disorders1/1650/832/67
Gastrointestinal haemorrhageGastrointestinal disorders3/1652/832/67
Upper gastrointestinal haemorrhageGastrointestinal disorders0/1650/832/67
Most frequent other events
Showing 10 of 46
Most frequent other events
EventNilotinib(Core +Extension)Control(Core + Extension)Crossover Nilotinib Therapy
NauseaGastrointestinal disorders51/16533/8313/67
Abdominal painGastrointestinal disorders61/16519/8313/67
Oedema peripheralGeneral disorders30/16526/8313/67
VomitingGastrointestinal disorders33/16525/8314/67
Weight decreasedInvestigations34/1657/8320/67
Decreased appetiteMetabolism and nutrition disorders47/16518/8316/67
AstheniaGeneral disorders46/1656/839/67
FatigueGeneral disorders46/16515/8312/67
ConstipationGastrointestinal disorders41/1659/8310/67
DiarrhoeaGastrointestinal disorders28/16520/835/67

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)NilotinibControl/Cross Over to NilotinibTotal
<=18 years000
Between 18 and 65 years11857175
>=65 years472673
Age Continuous
Age Continuous(years)NilotinibControl/Cross Over to NilotinibTotal
Mean57.4 ± 12.6958.6 ± 10.5757.8 ± 12.01
Sex: Female, Male
Sex: Female, Male(Participants)NilotinibControl/Cross Over to NilotinibTotal
Female6436100
Male10147148
Race (NIH/OMB)
Race (NIH/OMB)(Participants)NilotinibControl/Cross Over to NilotinibTotal
American Indian or Alaska Native000
Asian211132
Native Hawaiian or Other Pacific Islander202
Black or African American246
White13467201
More than one race000
Unknown or Not Reported617
08

Study locations

35 sites
  • UCLA's Jonsson Comprehensive Cancer Center
    Los Angeles, California 90095, United States
  • Washington Hospital Center - Washington Cancer Institute
    Washington, District of Columbia 20010-2965, United States
  • H. Lee Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • University of Chicago Hospital
    Chicago, Illinois 60637, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • Wayne State University/Wertz Clinical Cancer Center
    Detroit, Michigan 48201, United States
  • Washington University School of Medicine - Siteman Cancer Center
    St. Louis, Missouri 63110, United States
  • St. Vincent's Comprehensive Cancer Center
    New York, New York 10011, United States
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27157-1082, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111-2497, United States
  • University of Texas/MD Anderson Cancer Center
    Houston, Texas 77030-4009, United States
  • Novartis Investigative Site
    Auchenflower, Queensland 4066, Australia
  • Novartis Investigative Site
    East Melbourne, Victoria 3002, Australia
  • Novartis Investigative Site
    Vienna, Austria
  • Novartis Investigative Site
    Toronto, Canada
  • Novartis Investigative Site
    Praha 5, Czech Republic
  • Novartis Investigative Site
    Bordeaux, France
  • Novartis Investigative Site
    Lyon, France
  • Novartis Investigative Site
    Marseille, France
  • Novartis Investigative Site
    Berlin, Germany
  • Novartis Investigative Site
    Duesseldorf, Germany
  • Novartis Investigative Site
    Essen, Germany
  • Novartis Investigative Site
    Frankfurt, Germany
  • Novartis Investigative Site
    Hannover, Germany
  • Novartis Investigative Site
    Koln, Germany
  • Novartis Investigative Site
    Mannheim, Germany
  • Novartis Investigative Site
    Muenchen, Germany
  • Novartis Investigative Site
    Tubingen, Germany
  • Novrtis Investigative Site
    Bologna, Italy
  • Novartis Investigative Site
    Milan, Italy
  • Novartis Investigative Site
    Seoul, Korea, Republic of
  • Novartis Investigative Site
    Leiden, Netherlands
  • Novartis Investigative Site
    Warszawa, Poland
  • Novartis Investigative Site
    Madrid, Spain
  • Novartis Investigative Site
    Chur, Switzerland
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2007, a primary completion of Aug 2008 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.

Results were first posted in May 2011, 2 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2007
First posted
May 9, 2007
Start
Mar 2007
Primary completionActual
Aug 2008
CompletionActual
Jun 2011
Results first posted
May 17, 2011
Last update
Jun 12, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00471328
Responsible party
Sponsor
First posted
May 9, 2007
Start date
Mar 2007
Primary completion
Aug 2008
Completion
Jun 2011
Results posted
May 17, 2011
Last update
Jun 12, 2012

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nilotinib

Start the discussion